Physician profile
Lawrence Crafa
NPI 1568400760
$6,954.16
in general payments reported to CMS, 2019-2025
38 companies · $912 in 2025
The $912 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $867 · 2020: $1,005 · 2021: $1,101 · 2022: $950 · 2023: $896 · 2024: $1,223 · 2025: $912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,031.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,013.29 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $972.19 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $642.42 | 2019-2025 | |
| Novo Nordisk INC | $537.57 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $399.66 | 2020-2025 | Ubrelvy, Viberzi, Linzess |
| Glaxosmithkline, LLC. | $389.13 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Kowa Pharmaceuticals America, INC. | $356.59 | 2019-2022 | |
| Amarin Pharma, INC. | $297.48 | 2019-2023 | |
| Amgen INC. | $264.68 | 2020-2025 | Repatha, Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $205.90 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $193.54 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Janssen Pharmaceuticals, INC | $176.97 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $164.48 | 2019-2024 | Veozah |
| Allergan, INC. | $159.16 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $123.66 | 2022-2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Crafa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.